These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 23537667)

  • 21. Benzylguanidine and Galactose Double-Conjugated Chitosan Nanoparticles with Reduction Responsiveness for Targeted Delivery of Doxorubicin to CXCR 4 Positive Tumors.
    Kong F; Tang C; Yin C
    Bioconjug Chem; 2020 Oct; 31(10):2446-2455. PubMed ID: 32991164
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro and in vivo study of Gal-OS self-assembled nanoparticles for liver-targeting delivery of doxorubicin.
    Guo H; Zhang D; Li T; Li C; Guo Y; Liu G; Hao L; Shen J; Qi L; Liu X; Luan J; Zhang Q
    J Pharm Sci; 2014 Mar; 103(3):987-93. PubMed ID: 24549734
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Robust PEGylated hyaluronic acid nanoparticles as the carrier of doxorubicin: mineralization and its effect on tumor targetability in vivo.
    Han HS; Lee J; Kim HR; Chae SY; Kim M; Saravanakumar G; Yoon HY; You DG; Ko H; Kim K; Kwon IC; Park JC; Park JH
    J Control Release; 2013 Jun; 168(2):105-14. PubMed ID: 23474029
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor cells-specific targeting delivery achieved by A54 peptide functionalized polymeric micelles.
    Du YZ; Cai LL; Liu P; You J; Yuan H; Hu FQ
    Biomaterials; 2012 Dec; 33(34):8858-67. PubMed ID: 22959183
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chitosan/o-carboxymethyl chitosan nanoparticles for efficient and safe oral anticancer drug delivery: in vitro and in vivo evaluation.
    Feng C; Wang Z; Jiang C; Kong M; Zhou X; Li Y; Cheng X; Chen X
    Int J Pharm; 2013 Nov; 457(1):158-67. PubMed ID: 24029170
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhanced Penetrability of a Tetrahedral Framework Nucleic Acid by Modification with iRGD for DOX-Targeted Delivery to Triple-Negative Breast Cancer.
    Liu M; Ma W; Zhao D; Li J; Li Q; Liu Y; Hao L; Lin Y
    ACS Appl Mater Interfaces; 2021 Jun; 13(22):25825-25835. PubMed ID: 34038071
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peptide dendrimer-Doxorubicin conjugate-based nanoparticles as an enzyme-responsive drug delivery system for cancer therapy.
    Zhang C; Pan D; Luo K; She W; Guo C; Yang Y; Gu Z
    Adv Healthc Mater; 2014 Aug; 3(8):1299-308. PubMed ID: 24706635
    [TBL] [Abstract][Full Text] [Related]  

  • 28. RGD peptide-mediated chitosan-based polymeric micelles targeting delivery for integrin-overexpressing tumor cells.
    Cai LL; Liu P; Li X; Huang X; Ye YQ; Chen FY; Yuan H; Hu FQ; Du YZ
    Int J Nanomedicine; 2011; 6():3499-508. PubMed ID: 22282676
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bromelain-decorated hybrid nanoparticles based on lactobionic acid-conjugated chitosan for in vitro anti-tumor study.
    Wei B; He L; Wang X; Yan GQ; Wang J; Tang R
    J Biomater Appl; 2017 Aug; 32(2):206-218. PubMed ID: 28618976
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Matrix metalloproteinase-sensitive size-shrinkable nanoparticles for deep tumor penetration and pH triggered doxorubicin release.
    Ruan S; Cao X; Cun X; Hu G; Zhou Y; Zhang Y; Lu L; He Q; Gao H
    Biomaterials; 2015 Aug; 60():100-10. PubMed ID: 25988725
    [TBL] [Abstract][Full Text] [Related]  

  • 31. pH-sensitive chitosan-derived nanoparticles as doxorubicin carriers for effective anti-tumor activity: preparation and in vitro evaluation.
    Jin YH; Hu HY; Qiao MX; Zhu J; Qi JW; Hu CJ; Zhang Q; Chen DW
    Colloids Surf B Biointerfaces; 2012 Jun; 94():184-91. PubMed ID: 22405470
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of molecular weight on the oleoyl-chitosan nanoparticles as carriers for doxorubicin.
    Zhang J; Chen XG; Sun GZ; Huang L; Cheng XJ
    Colloids Surf B Biointerfaces; 2010 Jun; 77(2):125-30. PubMed ID: 20172698
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cationic poly-L-lysine dendrimer complexes doxorubicin and delays tumor growth in vitro and in vivo.
    Al-Jamal KT; Al-Jamal WT; Wang JT; Rubio N; Buddle J; Gathercole D; Zloh M; Kostarelos K
    ACS Nano; 2013 Mar; 7(3):1905-17. PubMed ID: 23527750
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis and characterization of amphiphilic glycidol-chitosan-deoxycholic acid nanoparticles as a drug carrier for doxorubicin.
    Zhou H; Yu W; Guo X; Liu X; Li N; Zhang Y; Ma X
    Biomacromolecules; 2010 Dec; 11(12):3480-6. PubMed ID: 21028798
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Self-assembled nanoparticles based on hydrophobically modified chitosan as carriers for doxorubicin.
    Zhang J; Chen XG; Li YY; Liu CS
    Nanomedicine; 2007 Dec; 3(4):258-65. PubMed ID: 17962086
    [TBL] [Abstract][Full Text] [Related]  

  • 36. pH triggered doxorubicin delivery of PEGylated glycolipid conjugate micelles for tumor targeting therapy.
    Hu FQ; Zhang YY; You J; Yuan H; Du YZ
    Mol Pharm; 2012 Sep; 9(9):2469-78. PubMed ID: 22827551
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhancing Accumulation and Penetration of HPMA Copolymer-Doxorubicin Conjugates in 2D and 3D Prostate Cancer Cells via iRGD Conjugation with an MMP-2 Cleavable Spacer.
    Peng ZH; Kopeček J
    J Am Chem Soc; 2015 Jun; 137(21):6726-9. PubMed ID: 25963409
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor targeting efficiency of bare nanoparticles does not mean the efficacy of loaded anticancer drugs: importance of radionuclide imaging for optimization of highly selective tumor targeting polymeric nanoparticles with or without drug.
    Lee BS; Park K; Park S; Kim GC; Kim HJ; Lee S; Kil H; Oh SJ; Chi D; Kim K; Choi K; Kwon IC; Kim SY
    J Control Release; 2010 Oct; 147(2):253-60. PubMed ID: 20624433
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Co-delivery of PDTC and doxorubicin by multifunctional micellar nanoparticles to achieve active targeted drug delivery and overcome multidrug resistance.
    Fan L; Li F; Zhang H; Wang Y; Cheng C; Li X; Gu CH; Yang Q; Wu H; Zhang S
    Biomaterials; 2010 Jul; 31(21):5634-42. PubMed ID: 20430433
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biodistribution and anti-tumor efficacy of doxorubicin loaded glycol-chitosan nanoaggregates by EPR effect.
    Son YJ; Jang JS; Cho YW; Chung H; Park RW; Kwon IC; Kim IS; Park JY; Seo SB; Park CR; Jeong SY
    J Control Release; 2003 Aug; 91(1-2):135-45. PubMed ID: 12932645
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.